We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 1

Figure 1. From: Making Therapeutic Decisions in IBD: The Role of Patients.

Maximum acceptable annual risk for adverse events depending on the level of the benefit of Crohn’s disease treatment. Patients were willing to accept a higher risk of adverse events in exchange for greater treatment benefit (14).
MAR = maximum acceptable risk; PML = progressive multifocal lymphadenopathy; Mild, moderate, severe relate to severity of Crohn’s disease symptoms.
This figure is reproduced from Siegel CA. Communicating the risks of inflammatory bowel disease medications to patients. Inflamm Bowel Dis Monit;2008(3):78-83.

Corey A. Siegel. Curr Opin Gastroenterol. ;25(4):334-338.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is temporarily unavailable.

Write to the Help Desk